Skip to main content
. Author manuscript; available in PMC: 2020 Aug 1.
Published in final edited form as: Invest Radiol. 2019 Aug;54(8):485–493. doi: 10.1097/RLI.0000000000000569

Table 4:

Best-performance cut-off values for T1, T2 and ADC based on regression models. For multivariate regression models, the individual cut-off values contributed independently to overall performance. The numbers in parenthesis indicate sensitivity and specificity for respective cut-off values.

Groups Compared T1
(Sensitivity/
Specificity)		 T2
(Sensitivity/
Specificity)		 ADC
(Sensitivity/
Specificity)
All Prostate cancers versus Non-Cancers
Prostate Cancer (n=63) vs. Prostatitis (n=15) Regression model not significant 68 ms (79%67%) 1.04×10−3 mm2/s (98%/53%)
Prostate Cancer (n=63) vs. Negative Biopsies (n=26) 1720 ms (68%/62%) Regression model not significant 0.75×10−3 mm2/s (62%/92%)
Prostate Cancer (n=63) vs. Non-cancers (n=41) 1720 ms (67%/59%) 67 ms (79%/46%) 0.75×10−3 mm2/s (62%/87.5%)
Clinically-significant (CS) cancers versus other histologic groups
CS Cancer (n=53) vs. Low-grade cancers (n=10) Regression model not significant 52 ms (62%/90%) 0.78×10−3 mm2/s (73.5%/80%)
CS Cancer (n=53) vs. Non-cancers (n=41) 1720 ms (68%/58/5%) 52 ms (62%/71%) 0.75×10−3 mm2/s (70%87.5%)
CS Cancer (n=53) vs. Clinically Insignificant lesions (Non-cancers + Low-grade cancers) (n=51) 1730 ms (68%/55%) 60 ms (62%/74.5%) 0.75×10−3 mm2/s (70%/86%)